With the continued focus on evidence-based medicine, new randomized controlled trials (RCTs) are needed in vasculitis to improve management of these conditions. In this Opinion article, using antineutrophil cytoplasmic antibody-associated and large-vessel vasculitis as examples, Tarzi and colleagues discuss RCTs performed to date and outline important issues in trial design and future directions for the field.
- Ruth M. Tarzi
- Justin C. Mason
- Charles D. Pusey